KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Net Margin (2016 - 2025)

Vertex Pharmaceuticals has reported Net Margin over the past 17 years, most recently at 37.34% for Q4 2025.

  • Quarterly results put Net Margin at 37.34% for Q4 2025, up 599.0% from a year ago — trailing twelve months through Dec 2025 was 32.94% (up 3780.0% YoY), and the annual figure for FY2025 was 32.94%, up 3780.0%.
  • Net Margin for Q4 2025 was 37.34% at Vertex Pharmaceuticals, up from 35.2% in the prior quarter.
  • Over the last five years, Net Margin for VRTX hit a ceiling of 42.94% in Q3 2021 and a floor of 135.83% in Q2 2024.
  • Median Net Margin over the past 5 years was 36.82% (2022), compared with a mean of 26.08%.
  • Biggest five-year swings in Net Margin: plummeted -17256bps in 2024 and later soared 17067bps in 2025.
  • Vertex Pharmaceuticals' Net Margin stood at 37.16% in 2021, then dropped by -4bps to 35.56% in 2022, then increased by 8bps to 38.48% in 2023, then dropped by -19bps to 31.35% in 2024, then increased by 19bps to 37.34% in 2025.
  • The last three reported values for Net Margin were 37.34% (Q4 2025), 35.2% (Q3 2025), and 34.84% (Q2 2025) per Business Quant data.